$202 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 17 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | PDL BIOPHARMA INCnote 2.875% 2/15/15 | $37,556,000 | -13.8% | 25,974,000 | -16.1% | 18.60% | +8.3% | |
| Sell | OPKO HEALTH INCnote 3.0% 2/1/33 | $30,939,000 | +0.5% | 25,000,000 | -15.3% | 15.32% | +26.3% | |
| SLXP | SALIX PHARMACEUTICALS INC | $20,064,000 | +1.1% | 300,000 | 0.0% | 9.94% | +27.1% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $17,898,000 | – | 1,181,400 | +100.0% | 8.86% | – |
| Sell | MANNKIND CORPnote 3.750% 12/15/13 | $17,110,000 | -49.1% | 17,144,000 | -49.8% | 8.47% | -36.1% | |
| DENDREON CORPnote 2.875% 1/15/16 | $16,191,000 | -15.2% | 26,515,000 | 0.0% | 8.02% | +6.6% | ||
| INTERMUNE INCnote 2.50% 9/15/18 | $15,263,000 | +8.5% | 17,000,000 | 0.0% | 7.56% | +36.4% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $13,157,000 | +29.5% | 182,300 | 0.0% | 6.52% | +62.7% | |
| OGXI | ONCOGENEX PHARMACEUTICALS INC | $8,650,000 | -5.4% | 933,100 | 0.0% | 4.28% | +18.9% | |
| SAVIENT PHARMACEUTICALS INCnote 4.750% 2/1/18 | $7,314,000 | +60.0% | 30,476,000 | 0.0% | 3.62% | +101.1% | ||
| DEPO | Sell | DEPOMED INC | $6,244,000 | -39.7% | 835,931 | -54.6% | 3.09% | -24.2% |
| ECYT | ENDOCYTE INC | $6,209,000 | +1.5% | 465,763 | 0.0% | 3.08% | +27.6% | |
| CORSICANTO LTDnote 3.50% 1/15/32 | $2,762,000 | +1.5% | 2,500,000 | 0.0% | 1.37% | +27.5% | ||
| SPHS | New | SOPHIRIS BIO INC | $2,340,000 | – | 500,000 | +100.0% | 1.16% | – |
| DNDNQ | DENDREON CORP | $233,000 | -29.0% | 79,600 | 0.0% | 0.12% | -10.9% | |
| AMBI | AMBIT BIOSCIENCES CORP | $0 | – | 46 | 0.0% | 0.00% | – | |
| CYCC | Exit | CYCLACEL PHARMACEUTICALS INC | $0 | – | -73,895 | -100.0% | -0.09% | – |
| Exit | SUPERNUS PHARMACEUTICALS INCnote 7.5% 5/1/19 | $0 | – | -10,000,000 | -100.0% | -0.49% | – | |
| RMTI | Exit | ROCKWELL MEDICAL INC | $0 | – | -448,146 | -100.0% | -0.64% | – |
| NAVB | Exit | NAVIDEA BIOPHARMACEUTICALS INC | $0 | – | -868,079 | -100.0% | -0.91% | – |
| MNKD | Exit | MANNKIND CORP | $0 | – | -1,184,784 | -100.0% | -3.04% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -911,053 | -100.0% | -4.15% | – |
| Exit | PACIRA PHARMACEUTICALS INCnote 3.25% 2/1/19 | $0 | – | -18,500,000 | -100.0% | -10.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.